Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
- RR 1.42 [0.6, 3.33]1 study · 129 participantsVery low